Posts tagged CEO
Microbix appoints Cameron Groome as President, CEO

Microbix Biosystems (TSX:MBX) has appointed Cameron Groome as its president and CEO, with Vaughn Embro-Pantalony retiring from those positions but remaining an executive director, working closely with Mr. Groome to ensure a smooth leadership transition.

Read More
Tetra Bio-Pharma names Bernard Fortier as CEO

Tetra BioPharma (OTCQB:TBPMF; CSE:TBP) appointed Bernard Fortier to the position of CEO, effective July 24. 

Read More
Valeant to commercialize Contrave in Canada

Valeant Canada, a subsidiary of Valeant Pharmaceuticals International (NYSE, TSX: VRX), will commercialize Orexigen Therapeutics’ (NASDAQ:OREX) Contrave (naltrexone HCl / bupropion HCl extended release) in Canada.

Under the accord, Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activity and expenses. Orexigen will supply Contrave tablets to Valeant Canada or its affiliates for an agreed transfer price and certain potential regulatory and sales milestone payments. Orexigen expects Valeant to file with Health Canada for regulatory approval by January 2017.

Read More
Profound Medical names Arun Menawat as CEO

Profound Medical (TSX-V:PRN) appointed Arun Menawat as its new CEO.  Steven Plymale, the company’s current CEO, will transition to President and COO.

Dr. Menawat has been a member of Profound’s board since October 2014. Most recently, he was president and CEO of Novadaq Technologies, which pioneered the field of fluorescence imaging in the operating room.

Read More
Soricimed announces members of CAB

Closely-held Soricimed Biopharma has announced the members of its newly formed Clinical Advisory Board (CAB).

The CAB, comprising key thought leaders in the treatment of cancer and novel anti-cancer targets, will provide Soricimed with ongoing expert strategic guidance on the continued clinical development of its lead anti-cancer drug candidate, SOR-C13, and its preclinical oncology pipeline.

Read More
Joint Corp. names Peter Holt as acting CEO

The employment of John Richards as CEO of the Joint Corp. (NASDAQ:JYNT) has been terminated by mutual agreement, effective June 30.  Mr. Richards also resigned as a director. Peter Holt, who was previously COO, was named acting CEO.

In a statement, Richard Kerley, lead director, said the board has complete confidence in Mr. Holt’s operational and leadership abilities. “Mr. Holt was recruited with a view to the board’s responsibility for succession planning, and we look forward to supporting him as he applies his considerable skill and experience to fulfilling our commitments to our shareholders, franchisees and associates.”

Read More
Nobilis Health appoints chief accounting officer

Nobilis Health (NYSE MKT:HLTH; TSX:NHC) has appointed Marcos Rodriguez as chief accounting officer.

Mr. Rodriguez brings over 17 years of diversified accounting experience to the company. Prior to joining Nobilis, he served for five years as director in complex financial reporting and enterprise risk at Opportune LLP, and 11 years at Deloitte & Touche as audit senior manager in audit & enterprise risk services.

Read More
Dipexium completes enrollment in one Locilex Phase 3 trial

Dipexium Pharmaceuticals (NASDAQ:DPRX) has completed the patient enrollment objective in the OneStep-2 Phase 3 clinical trial of its Locilex topical antibiotic peptide.

The company’s OneStep-1 Phase 3 clinical trial has passed the 98% enrollment mark and is expected to reach the 180-patient enrollment objective soon.

Read More
Nobilis Health Q1 revenue climbs 35%

First quarter revenue for Nobilis Health (NYSE MKT:HLTH; TSX:NHC) rose 35% to a record $51.3-million, driven by increased case flow and a higher average revenue per case.

In the first quarter, we invested heavily in new technology and infrastructure to support our forecasted growth in 2016,” CEO, Harry Fleming, said in a statement.

Read More